PASD1

Across TCGA pan-cancer cohorts, PASD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PASD1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PASD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PASD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LUAD, and LUSC are the cancer types where PASD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.172	0.708	<.001	36	view →
LUAD	DFS	Median	IV	0.109	0.714	.001	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.031	6	view →
LIHC	OS	Median	All	0.047	0.783	<.001	6	view →
UCEC	DFS	Median	All	0.937	0.827	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PASD1–ESCA (OS)

Open the ESCA breakdown →